济南前列腺尿频难治吗济南性功能减退怎么回事,济南射得很快,济南非细菌性前列腺炎的症状,济南睾丸一个大,济南早谢了怎么办,济南男人早泄,济南性功能疾病常规检查

BEIJING, Oct. 1 (Xinhua) -- China plans to decrease leprosy rates by 50 percent over the next 10 years, according to a joint plan to fight the infectious disease issued by the Ministry of Health and ten other ministerial-level institutions.The prevalence rate is targeted to be brought down to one case per 10,000 people by 2015. The rate will further shrink to one in every 100,000 people by 2020 in at least 98 percent of the country's counties, according to the plan.A total of 500,000 cases of leprosy have been reported and treated for free throughout the country since the founding of the People's Republic of China on Oct. 1, 1949.The number of leprosy cases has plummeted over the past 62 years, but the country still faces challenges in fighting the disease, the plan said.Leprosy, an infectious disease that has affected humanity for over 4,000 years, is primarily characterized by skin lesions and progressive physical debility, and can cause permanent nerve damage.Despite sustained efforts -- and considerable success -- in bringing the disease under control, leprosy is still a serious disease in some parts of China and people who have been cured of the disease continue to face discrimination.More than 1,700 new cases have been reported annually in the past five years. The provinces of Sichuan, Yunnan, Guizhou and Hunan and the Tibet Autonomous Region are most affected by the disease, according to the plan.

BEIJING, Jan. 9 (Xinhua) -- The United States Treasury Secretary Timothy Geithner will discuss economic ties and exchange views with Chinese officials on the global economic situation during his trip to China, Foreign Ministry spokesman Liu Weimin said on Monday.Liu said at a regular press briefing that Geithner will visit China from Jan. 10 to 11 as the U.S. President's special representative. Premier Wen Jiabao, Vice President Xi Jinping, Vice Premier Li Keqiang and Vice Premier Wang Qishan will meet with him during the visit.Liu said China and the U.S. have agreed to build a partnership of cooperation based on mutual respect and mutual benefit."The global economic and financial situation is facing severe challenges. Further strengthening China-U.S. economic and trade cooperation will be helpful in meeting these challenges," Liu said."China has proposed further promoting the two countries' economic and trade cooperation and hopes the U.S. will work with China toward this end," Liu said.

BEIJING, Oct. 11 (Xinhuanet) -- An experimental drug that can remove amyloid plaques from the brains of Alzheimer's patients is being developed by Swiss Roche Holding AG in a small early-stage study, according to a report published in the Archives of Neurology on Monday.Researchers suspect the build-up of such plaques may be a cause of the memory robbing disease, although that theory has yet to be definitively proved. Gantenerumab, a biotech drug designed to bind to amyloid plaques in the brain and remove them, is being targeted at the early stages of Alzheimer's with the hope it can slow progression of the disease while patients are still able to function.The Phase I study of 16 Alzheimer's patients tested gantenerumab at two doses against a placebo over six months of treatment.The Roche drug led to a dose-dependent reduction of brain amyloid, while amyloid load increased in patients receiving a placebo, the report said.The next step will be to investigate whether removal of brain amyloid translates into clinical benefit for patients at doses of the experimental drug that are well tolerated and safe, the report said.Much larger trials and further study will be needed to fully understand how gantenerumab works and whether it can stave off Alzheimer's, said the report.Roche is approaching the disease far earlier because amyloid accumulates for 15 years before dementi.

SAN FRANCISCO, Nov. 12 (Xinhua) -- Apple has unveiled a worldwide replacement program for the first-generation iPod nano music player due to overheating battery issues, telling owners to stop using the product and get it replaced for free."Apple has determined that, in very rare cases, the battery in the iPod nano (1st generation) may overheat and pose a safety risk. Affected iPod nanos were sold between September 2005 and December 2006," said Apple in a notice posted late Friday on the support section of its official website.The company said the issue has been traced to a single battery supplier that produced batteries with a manufacturing defect. Since the product is five or six years old now, the likelihood of an incident increases.Owners of iPod nano can check the serial number on the back of the product to see if it is eligible for replacement. Apple promises a replacement unit about six weeks after the company received the affected one.The overheating battery issues of the first generation iPod nano have been known for years. In 2008, Japan's Ministry of Economy, Trade and Industry launched an investigation into Apple after dozens of iPod overheating cases were reported, including several incidents of iPod nanos toasting to the point of catching fire and causing minor burns to owners.Last August, a commuter train in Tokyo was delayed during rush hour when passengers complained of a strong burning smell from an overheating iPod nano that had burst apart.The portable music player also cost Apple a 22.5 million-U.S. dollar settlement in 2009 when a class action lawsuit in California alleged iPod nano is prone to scratches and its alleged defects were not disclosed by the company.

WASHINGTON, Dec. 7 (Xinhua) -- The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.Their report, published on-line Wednesday in Gynecologic Oncology, suggests that this combination, ixabepilone and sunitinib, might offer a much needed treatment option for women with advanced ovarian cancer.Neither drug is approved for use in ovarian cancer. Ixabepilone is a chemotherapy drug that, like other taxane drugs, targets the microtubules and stops dividing cells from forming a spindle. It has been approved for use in metastatic breast cancer. Sunitinib, approved for use in kidney cancer, belongs to a class of tyrosine kinase inhibitors that stops growth signals from reaching inside cancer cells.When caught at late stages, ovarian cancer is often fatal because it progressively stops responding to the chemotherapy drugs used to treat it."Women die from ovarian cancer because their tumors become resistant to chemotherapy, so a drug that might be able to reduce that resistance -- which may be what this combination of agents is doing -- would be a boon to treatment of this difficult cancer," says study coauthor Gerardo Colon-Otero.The finding also highlights the importance of the role of a molecule, RhoB, that the researchers say is activated by the drug duo. It might be a potential biomarker that may help identify patients who might benefit from such combination therapy, the researchers say.